Mylan N.V. is a global pharmaceutical company with a well-established generics business as well as a presence in specialty pharmaceuticals. The company’s business model includes the development, manufacturing and marketing of branded and generic drugs as well as active pharmaceutical ingredients (APIs) in North America, Europe and Rest of World. Notably, Mylan has one of the world’s largest API operations.
Mylan has been making prudent acquisitions and inking strategic deals to drive long-term growth. In Feb 2015, the company acquired Abbott Laboratories’ non-U.S. developed markets’ specialty and branded generics business. Further, in Nov 2015, it acquired certain female health care businesses of Famy Care.
However, Mylan has been under immense pressure since Aug 2016 when the company faced criticism for the price increase of EpiPen since its acquisition of the drug in 2007 from lawmakers, consumers and the common people alike.
Mylan’s performance has been decent so far, having beaten earnings estimates in three of the trailing four quarters and missing once. Overall, it has delivered an average positive surprise of 1.39%. Last quarter, the company recorded a positive earnings surprise of 11.3%.
Currently, Mylan has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mylan beat on earnings. Our consensus called for EPS of $0.92, and the company reported EPS of $0.93.
Revenue: Revenues however missed expectations. Mylan posted revenues of $2.72 billion, compared to our consensus estimate of $2.83 billion.
Key Stats: Strong double-digit revenue growth in Europe and Rest of World and a solid performance in North America contributed to year over year growth in revenues.
Check back later for our full write up on this Mylan earnings report later!
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Image: Bigstock
Mylan (MYL) Tops on Q1 Earnings
Mylan N.V. is a global pharmaceutical company with a well-established generics business as well as a presence in specialty pharmaceuticals. The company’s business model includes the development, manufacturing and marketing of branded and generic drugs as well as active pharmaceutical ingredients (APIs) in North America, Europe and Rest of World. Notably, Mylan has one of the world’s largest API operations.
Mylan has been making prudent acquisitions and inking strategic deals to drive long-term growth. In Feb 2015, the company acquired Abbott Laboratories’ non-U.S. developed markets’ specialty and branded generics business. Further, in Nov 2015, it acquired certain female health care businesses of Famy Care.
However, Mylan has been under immense pressure since Aug 2016 when the company faced criticism for the price increase of EpiPen since its acquisition of the drug in 2007 from lawmakers, consumers and the common people alike.
Mylan’s performance has been decent so far, having beaten earnings estimates in three of the trailing four quarters and missing once. Overall, it has delivered an average positive surprise of 1.39%. Last quarter, the company recorded a positive earnings surprise of 11.3%.
Mylan N.V. Price and EPS Surprise
Mylan N.V. Price and EPS Surprise | Mylan N.V. Quote
Currently, Mylan has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mylan beat on earnings. Our consensus called for EPS of $0.92, and the company reported EPS of $0.93.
Revenue: Revenues however missed expectations. Mylan posted revenues of $2.72 billion, compared to our consensus estimate of $2.83 billion.
Key Stats: Strong double-digit revenue growth in Europe and Rest of World and a solid performance in North America contributed to year over year growth in revenues.
Check back later for our full write up on this Mylan earnings report later!
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>